ArticleJACC. Heart failure2021
Advanced Heart Failure Epidemiology and Outcomes: A Population-Based Study.
Article in JACC. Heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07445932 (The PALL-VAD Study), which is not on this map. Cited by 97 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The PALL-VAD Study: Palliative Care Intervention to Improve Health Related Quality of Life for Patients With Heart Failure on Long-Term LVAD Support: A Pilot, Prospective, Randomized Trial
Who cites it
97 citing papers in PubMed, 5 syntheses or guidelines pooled it, 152 citations in OpenAlex.
- Ventricular arrhythmias following left ventricular assist device implantation: a systematic review and meta-analysis of incidence and clinical impact.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Pooled it
- Cost Effectiveness of Left Ventricular Assist Devices (LVADs) as Destination Therapy: A Systematic Review.PharmacoEconomics - open · 2025Pooled it
- Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- Development and Validation of a Protein Risk Score for Mortality in Heart Failure : A Community Cohort Study.Annals of internal medicine · 2024Pooled it
- Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial.Nature medicine · 2026Trial
- Finerenone in patients with severe heart failure: The FINEARTS-HF trial.European journal of heart failure · 2025Trial
- Comment on "Stage D heart failure in the United States: A study from a national database".American heart journal plus : cardiology research and practice · 2026Article
- Control of cardiotoxicity via nasal in-situ pH-sensitive transbilosomal formulation of candesartan.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Economic evaluation of NT-proBNP testing plus standard clinical assessment versus standard clinical assessment alone for the prevention of heart failure in older adults with type 2 diabetes.BMJ open diabetes research & care · 2026Article
- Cross-Sectional Plasma Proteomic Phenotypes Associated with Prolonged Intermittent Levosimendan Exposure in Advanced Heart Failure.ACS pharmacology & translational science · 2026Article
- Device-Induced Blood Damage in Pump-Assisted Circulation: A Comparative Study of HeartMate III and BrioVAD Pumps.Artificial organs · 2026Article
- Prevalence of Clinically Recognized Phenotypes in Advanced Heart Failure.Journal of cardiac failure · 2026Article
- Management of dyslipidaemia in patients with comorbidities-facing the challenge: heart failure.European heart journal. Cardiovascular pharmacotherapy · 2026Review
- Safety of recombinant activated factor VII for bleeding use post Heart Mate III, left ventricular assist device implantation.JHLT open · 2026Article
- Cost-Effectiveness of NT-proBNP-Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real-World Evidence From the Hong Kong Diabetes Biobank.Diabetes, obesity & metabolism · 2026Article
- Stage D heart failure in the United States: A study from a national database.American heart journal plus : cardiology research and practice · 2026Article
- Prognostic Implication of Heart Failure With Reduced and Midrange Ejection Fraction in Adults With Congenital Heart Disease.CJC pediatric and congenital heart disease · 2026Article
- Palliative and End-of-Life Care Utilization in Cardiogenic Shock Complicating Acute Myocardial Infarction: A Population-Based Study.JACC. Advances · 2026Article
- Targeting cardiac myosin in HFrEF: mechanism, clinical evidence, and the role of omecamtiv mecarbil.Journal of cardiothoracic surgery · 2026Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesThe goal of this study was to evaluate the prevalence, characteristics, and outcomes of patients with advanced heart failure (HF) in a geographically defined population.
backgroundSome patients with HF progress to advanced HF, characterized by debilitating HF symptoms refractory to therapy. Limited data are available on the epidemiology and outcomes of patients with advanced HF.
methodsThis was a population-based cohort study of all Olmsted County, Minnesota, adults with and without HF from 2007 to 2017. The 2018 European Society of Cardiology advanced HF diagnostic criteria were operationalized and applied to all patients with HF. Hospitalization and mortality in advanced HF, overall and according to ejection fraction (EF) type (reduced EF <40% [HFrEF], mid-range EF 40%-49% [HFmrEF], and preserved EF ≥50% [HFpEF]) were examined using Andersen-Gill and Cox models.
resultsOf 6,836 adults with HF, 936 (13.7%) met criteria for advanced HF. The prevalence of advanced HF increased with age and was higher in men. At advanced HF diagnosis, 396 (42.3%) patients had HFrEF, 134 (14.3%) had HFmrEF, and 406 (43.4%) had HFpEF. The median (interquartile range) time from advanced HF diagnosis to death was 12.2 months (3.7-29.9 months). The mean rate of hospitalization was 2.91 (95% CI: 2.78-3.06) per person-year in the first year after advanced HF diagnosis. There were no differences in risks of all-cause mortality or hospitalization by EF. Patients with advanced HFpEF were at lower risk for cardiovascular mortality compared with advanced HFrEF (HR: 0.79; 95% CI: 0.65-0.97).
conclusionsIn this population-based study, more than one-half of patients with advanced HF had mid-range or preserved EF, and survival was poor regardless of EF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.